This article extends the work of BUYSE et al. (2000) on the validation of surrogate endpoints in a meta-analytic setting to the case of two discrete outcomes, the focus being on binary endpoints. The methodology entails fitting of a joint model for the surrogate and the true endpoints that includes several random effects. We propose to fit this model using a pairwise likelihood (PL) approach which seems better suited to the problem at hand than maximum likelihood or penalized quasi-likelihood. The performance of the PL estimator is evaluated on the grounds of limited simulations and the methodology is illustrated on data from a meta-analysis of five clinical trials comparing antipsychotic agents for the treatment of chronic schizophrenia.st...
In many therapeutic areas, the identification and validation of surrogate end points is of prime int...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
Part of the recent literature on the evaluation of biomarkers as surrogate endpoints starts from a m...
For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint i...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Biv...
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Biv...
OBJECTIVE: A schema was recently proposed for assessing the levels of evidence for surrogate validit...
The increasing cost of drug development has raised the demand for surrogate endpoints when evaluatin...
We investigate the effect of the choice of parameterisation of meta-analytic models and related unce...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
In randomized clinical trials, the evaluation of potential surrogate endpoints is very important, s...
We investigate the effect of the choice of parameterisation of meta-analytic models and related unce...
In many therapeutic areas, the identification and validation of surrogate end points is of prime int...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
Part of the recent literature on the evaluation of biomarkers as surrogate endpoints starts from a m...
For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint i...
The validation of surrogate endpoints has been studied by Prentice, who presented a definition as we...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Biv...
A number of meta-analytical methods have been proposed that aim to evaluate surrogate endpoints. Biv...
OBJECTIVE: A schema was recently proposed for assessing the levels of evidence for surrogate validit...
The increasing cost of drug development has raised the demand for surrogate endpoints when evaluatin...
We investigate the effect of the choice of parameterisation of meta-analytic models and related unce...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
In randomized clinical trials, the evaluation of potential surrogate endpoints is very important, s...
We investigate the effect of the choice of parameterisation of meta-analytic models and related unce...
In many therapeutic areas, the identification and validation of surrogate end points is of prime int...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
Part of the recent literature on the evaluation of biomarkers as surrogate endpoints starts from a m...